
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Today's presentations were all cme sessions with the opening ceremony in the evening and a welcome reception.
NOTES FROM PRAGUE: A EUROPEAN PERSPECTIVE
Saturday, March 3, 2012
Just flew into Prague. Off to the Prague Congress Center to finalize my registration and pick up materials. This is opening day of the




